[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-001", "question": "A 34-year-old woman presents with 6 months of progressive bilateral hand weakness and numbness. She has a 15-year history of systemic lupus erythematosus treated with hydroxychloroquine and low-dose prednisone. Examination reveals symmetric weakness of finger abduction and adduction bilaterally, decreased sensation to pinprick over the ulnar aspect of both hands, and absent ulnar deep tendon reflexes. Nerve conduction studies show reduced compound muscle action potential amplitudes in bilateral ulnar nerves with conduction block at the elbow, prolonged distal motor latencies, and temporal dispersion. Anti-ganglioside antibodies are negative. CSF shows protein 85 mg/dL with 2 WBCs. Which of the following is the most likely diagnosis?", "options": ["Multifocal motor neuropathy with conduction block", "Chronic inflammatory demyelinating polyneuropathy", "Lupus-associated mononeuritis multiplex", "Lewis-Sumner syndrome", "Hereditary neuropathy with liability to pressure palsies"], "answer": "D", "answer_index": 3, "explanation": "Lewis-Sumner syndrome (multifocal acquired demyelinating sensory and motor neuropathy, MADSAM) is characterized by asymmetric sensorimotor involvement with demyelinating features including conduction block, distinguishing it from multifocal motor neuropathy (purely motor, anti-GM1 positive) and CIDP (symmetric). The presence of sensory symptoms and signs excludes MMN. Lupus mononeuritis multiplex typically shows axonal rather than demyelinating features. HNPP would show conduction abnormalities at typical compression sites without temporal dispersion.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with progressive bilateral hand weakness and numbness, symmetric weakness of finger abduction and adduction, decreased sensation over the ulnar aspect of both hands, and absent ulnar deep tendon reflexes. Nerve conduction studies reveal reduced compound muscle action potential amplitudes in bilateral ulnar nerves with conduction block at the elbow, prolonged distal motor latencies, and temporal dispersion. The CSF shows elevated protein with a mild pleocytosis.\n\nLet's analyze the options:\n\nA. Multifocal motor neuropathy with conduction block (MMN) is characterized by progressive, asymmetric, and often proximal muscle weakness, typically affecting the upper limbs. Conduction block is a hallmark. While conduction block is present, the presentation is bilateral and symmetric, and sensory symptoms are also described, which are less typical for pure MMN.\n\nB. Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired demyelinating polyneuropathy that typically presents with progressive, symmetric, proximal and distal weakness and sensory loss. Nerve conduction studies show evidence of demyelination, including conduction block, prolonged distal latencies, and temporal dispersion. The CSF often shows elevated protein with mild pleocytosis. The patient's symptoms, nerve conduction findings, and CSF analysis are highly consistent with CIDP. The bilateral and symmetric nature of the weakness and sensory loss, along with the demyelinating features on NCS, strongly support this diagnosis.\n\nC. Lupus-associated mononeuritis multiplex is a vasculitic neuropathy that typically presents with asymmetric, multifocal involvement of individual nerves, leading to focal deficits. While lupus is present, the symmetric and diffuse nature of the symptoms and the demyelinating features on NCS are not typical for mononeuritis multiplex.\n\nD. Lewis-Sumner syndrome is a variant of CIDP characterized by distal symmetric weakness and sensory loss, often with prominent distal motor conduction block. While there are similarities, the description of weakness in finger abduction and adduction, and the conduction block at the elbow, are more broadly consistent with CIDP, which can encompass distal and proximal involvement.\n\nE. Hereditary neuropathy with liability to pressure palsies (HNPP) is an inherited disorder characterized by recurrent, transient nerve palsies, often triggered by pressure. It is a demyelinating neuropathy, but the presentation is typically episodic and related to mechanical stress, which is not described here. The progressive nature of the symptoms also argues against HNPP.\n\nConsidering the progressive, symmetric weakness and sensory loss, the demyelinating features on nerve conduction studies (conduction block, prolonged distal latencies, temporal dispersion), and the CSF findings, CIDP is the most fitting diagnosis. The presence of lupus is a comorbidity that can be associated with CIDP.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-002", "question": "A 28-year-old woman at 32 weeks gestation presents with sudden onset severe headache, visual disturbances, and confusion. Blood pressure is 178/112 mmHg. Laboratory studies show platelets 68,000/μL, LDH 890 U/L, AST 245 U/L, creatinine 1.8 mg/dL, and peripheral smear with schistocytes. She receives magnesium sulfate and labetalol. Emergent cesarean delivery is performed. Postpartum day 3, despite delivery, her platelet count drops to 42,000/μL, creatinine rises to 2.9 mg/dL, and she develops new neurological symptoms. ADAMTS13 activity returns at 58%. Which additional finding would most strongly support initiating eculizumab therapy?", "options": ["Positive direct antiglobulin test", "Complement factor H mutation on genetic testing", "Elevated soluble fms-like tyrosine kinase-1 levels", "Low C3 with normal C4 levels", "Presence of anti-phospholipid antibodies"], "answer": "B", "answer_index": 1, "explanation": "This presentation of postpartum thrombotic microangiopathy not resolving after delivery with ADAMTS13 >10% suggests complement-mediated TMA (atypical HUS) rather than TTP or HELLP syndrome. Complement factor H mutation confirms complement dysregulation and strongly supports eculizumab (C5 inhibitor) therapy. Low C3 with normal C4 suggests alternative pathway activation but is nonspecific. Elevated sFlt-1 would suggest ongoing preeclampsia-related pathology. Positive DAT would suggest Evans syndrome, and anti-phospholipid antibodies suggest catastrophic APS, both requiring different management.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with symptoms highly suggestive of severe preeclampsia with HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets). However, her condition is worsening postpartum despite delivery, and the ADAMTS13 activity is 58%, which is not severely deficient (<10%) as seen in typical TTP. The new neurological symptoms and worsening renal function, along with the persistent low platelets, suggest a thrombotic microangiopathy.\n\nLet's analyze the options in the context of potential underlying causes for a worsening thrombotic microangiopathy:\n\nA. Positive direct antiglobulin test (DAT) suggests autoimmune hemolytic anemia, which is not the primary driver of the microangiopathy described.\nB. Complement factor H mutation is associated with atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy that can be triggered by various factors, including pregnancy. aHUS is characterized by dysregulation of the alternative complement pathway.\nC. Elevated soluble fms-like tyrosine kinase-1 (sFLT-1) levels are characteristic of preeclampsia and are not directly indicative of a specific underlying cause for a worsening thrombotic microangiopathy postpartum.\nD. Low C3 with normal C4 levels suggests activation of the alternative complement pathway, which is a hallmark of aHUS. This finding would strongly support the diagnosis of aHUS and the rationale for eculizumab, a complement inhibitor.\nE. Presence of anti-phospholipid antibodies can be associated with various thrombotic events, including some forms of thrombotic microangiopathy, but it's not as specific for a complement-mediated process as option D.\n\nConsidering the patient's worsening condition postpartum, the presence of schistocytes, and the need to consider alternative diagnoses beyond severe preeclampsia/HELLP, a complement-mediated thrombotic microangiopathy like aHUS becomes a strong consideration. Eculizumab is a treatment for aHUS.\n\nOption D, low C3 with normal C4 levels, directly points to the activation of the alternative complement pathway, which is the underlying mechanism in aHUS. This finding would provide the strongest support for initiating eculizumab therapy, as eculizumab targets the complement cascade. While a complement factor H mutation (Option B) is a cause of aHUS, the functional evidence of complement activation (Option D) is more directly indicative of the need for complement inhibition at this moment.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-003", "question": "A 52-year-old man with hypertrophic cardiomyopathy and an ICD presents with recurrent appropriate shocks for ventricular tachycardia despite maximum tolerated doses of metoprolol and disopyramide. Echocardiogram shows septal thickness of 22 mm, LVOT gradient of 85 mmHg at rest, and moderate mitral regurgitation with systolic anterior motion. Cardiac MRI demonstrates 18% late gadolinium enhancement predominantly in the septum. Coronary angiography is normal. Which intervention is most likely to reduce his arrhythmia burden?", "options": ["Alcohol septal ablation", "Surgical septal myectomy with mitral valve repair", "Catheter ablation of ventricular tachycardia", "Addition of amiodarone to current regimen", "Cardiac transplantation evaluation"], "answer": "B", "answer_index": 1, "explanation": "In HCM patients with significant LVOT obstruction, extensive LGE (>15%), and recurrent VT, surgical myectomy is preferred over alcohol septal ablation because ASA creates additional scar that may be proarrhythmic. Myectomy reduces obstruction and allows concomitant mitral valve repair for SAM-related MR. The extensive LGE indicates high arrhythmic substrate burden. VT ablation addresses the arrhythmia but not the underlying obstruction driving symptoms. Amiodarone adds toxicity risk without addressing mechanism. Transplant is premature given available surgical options.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with symptomatic hypertrophic cardiomyopathy (HCM) refractory to medical therapy, characterized by significant LVOT obstruction, mitral regurgitation, and recurrent appropriate ICD shocks for ventricular tachycardia.\n\nOption A, alcohol septal ablation, is a less invasive procedure that reduces the LVOT gradient by causing infarction of the septal muscle. While it can improve symptoms and reduce the gradient, it does not directly address the arrhythmogenic substrate of HCM, which is often related to myocardial disarray and fibrosis. It is generally considered for patients with significant LVOT obstruction who are not surgical candidates or as a bridge to surgery.\n\nOption B, surgical septal myectomy with mitral valve repair, is the gold standard treatment for symptomatic obstructive HCM. Septal myectomy directly removes the hypertrophied muscle causing the obstruction, and mitral valve repair can address the systolic anterior motion and resulting regurgitation. This procedure not only reduces the LVOT gradient but also aims to improve the underlying myocardial architecture, potentially reducing the arrhythmogenic substrate. Given the recurrent VT despite maximal medical therapy, addressing the structural abnormality is crucial.\n\nOption C, catheter ablation of ventricular tachycardia, targets the electrical circuits causing the VT. While it can be effective in reducing VT burden, it is often less successful in HCM compared to other cardiomyopathies due to the diffuse and complex nature of the arrhythmogenic substrate. It is typically considered when other options have failed or are not feasible, and it doesn't address the underlying hemodynamic issues.\n\nOption D, addition of amiodarone, is an antiarrhythmic medication that can suppress VT. However, the patient is already on maximum tolerated doses of two other antiarrhythmics (metoprolol and disopyramide), and amiodarone has significant long-term toxicity. While it might offer some benefit, it is unlikely to be the *most* effective intervention given the underlying structural disease and recurrent shocks.\n\nOption E, cardiac transplantation evaluation, is reserved for patients with end-stage heart failure or intractable arrhythmias that cannot be managed by other means. While this patient has recurrent VT, he is not described as having end-stage heart failure, and other definitive treatments for HCM are available.\n\nConsidering the patient's severe symptoms, recurrent VT despite maximal medical therapy, significant LVOT obstruction, and systolic anterior motion of the mitral valve, surgical septal myectomy with mitral valve repair offers the most comprehensive approach to address both the hemodynamic obstruction and the underlying arrhythmogenic substrate, thereby being most likely to reduce his arrhythmia burden.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-004", "question": "A 45-year-old woman with dermatomyositis diagnosed 8 months ago presents with progressive dyspnea. She was initially treated with high-dose prednisone and azathioprine with improvement in proximal muscle weakness. CT chest shows new ground-glass opacities with peripheral consolidation in lower lobes. Pulmonary function tests reveal FVC 58% predicted, DLCO 42% predicted. Bronchoalveolar lavage shows 35% lymphocytes. She tests positive for anti-MDA5 antibodies. Which treatment approach offers the best chance of halting disease progression?", "options": ["Increase prednisone and add mycophenolate mofetil", "Triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide", "Rituximab with continued azathioprine", "Nintedanib with continued current immunosuppression", "Plasma exchange followed by IVIG maintenance"], "answer": "B", "answer_index": 1, "explanation": "Anti-MDA5 dermatomyositis-associated rapidly progressive interstitial lung disease carries high mortality and requires aggressive upfront combination immunosuppression. Japanese and international experience supports triple therapy with high-dose corticosteroids, a calcineurin inhibitor (tacrolimus or cyclosporine), and cyclophosphamide as the most effective approach for halting progression. Single-agent additions or rituximab have shown inferior outcomes in this specific antibody subset. Nintedanib is antifibrotic, not immunosuppressive. Plasma exchange lacks evidence in this context.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with progressive dyspnea, interstitial lung disease (ILD) characterized by ground-glass opacities and peripheral consolidation, reduced FVC and DLCO, and a lymphocytic bronchoalveolar lavage. She also has dermatomyositis and is positive for anti-MDA5 antibodies. Anti-MDA5 antibody-positive dermatomyositis is strongly associated with rapidly progressive ILD, which is often refractory to conventional immunosuppression.\n\nLet's analyze the options:\n\nA. Increase prednisone and add mycophenolate mofetil: While increasing immunosuppression is generally indicated, this combination might not be aggressive enough for rapidly progressive ILD associated with anti-MDA5 antibodies. Mycophenolate mofetil is a reasonable choice for dermatomyositis, but its efficacy in this specific severe ILD phenotype is less established compared to other options.\n\nB. Triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide: Cyclophosphamide is a potent immunosuppressant, but its use in ILD can be associated with significant toxicity, and it's not the first-line treatment for anti-MDA5 positive ILD. Calcineurin inhibitors (like tacrolimus or cyclosporine) are sometimes used in ILD, but the combination with cyclophosphamide might be overly aggressive and not specifically tailored to the anti-MDA5 phenotype.\n\nC. Rituximab with continued azathioprine: Rituximab is a B-cell depleting antibody that has shown promise in treating ILD associated with connective tissue diseases, including dermatomyositis. Given the B-cell involvement in autoimmune diseases and the potential for B-cell mediated inflammation in ILD, rituximab is a strong contender. Continued azathioprine provides ongoing immunosuppression.\n\nD. Nintedanib with continued current immunosuppression: Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing ILDs with a progressive phenotype. While this patient has ILD, the underlying cause is dermatomyositis, and the primary goal is to address the autoimmune process driving the ILD. Nintedanib targets the fibrotic process but does not directly treat the underlying autoimmune inflammation. However, in cases of rapidly progressive ILD, especially when conventional immunosuppression is failing, antifibrotic agents like nintedanib are increasingly considered to halt disease progression, even in the context of an autoimmune disease. Given the severity and progression, and the fact that current immunosuppression might not be sufficient, adding an antifibrotic agent is a valid strategy.\n\nE. Plasma exchange followed by IVIG maintenance: Plasma exchange and IVIG are typically used for acute, severe autoimmune flares, particularly those involving autoantibodies that can be removed by plasma exchange or neutralized by IVIG. While they can be part of a treatment strategy for severe dermatomyositis, they are less commonly the primary approach for halting progressive ILD in this context, especially when compared to agents that target the underlying immune dysregulation or fibrotic pathways.\n\nConsidering the anti-MDA5 antibody positivity and the rapidly progressive nature of the ILD, aggressive immunosuppression is crucial. Rituximab has demonstrated efficacy in ILD associated with connective tissue diseases. However, the question asks for the best chance of *halting disease progression*. Anti-MDA5 positive ILD is known for its rapid progression and poor response to standard immunosuppression. In such cases, a combination approach or an agent specifically targeting the fibrotic component might be considered.\n\nRecent literature and clinical guidelines suggest that for anti-MDA5 positive dermatomyositis with severe ILD, a combination of immunosuppressants, often including rituximab, or even antifibrotic agents like nintedanib, are considered. Nintedanib has shown efficacy in slowing the rate of lung function decline in various progressive fibrosing ILDs. Given the severity (FVC 58%, DLCO 42%) and progressive nature, nintedanib could be a crucial addition to prevent further irreversible lung damage, even if the underlying cause is autoimmune. The \"continued current immunosuppression\" implies that the prednisone and azathioprine will be maintained, and nintedanib would be added. This approach addresses both the potential ongoing inflammation and the fibrotic process.\n\nWhile rituximab is a strong option for the autoimmune component, the rapid progression and severity of the ILD might necessitate an antifibrotic agent to halt further irreversible damage. Therefore, nintedanib, in conjunction with continued immunosuppression, offers a strong chance of halting disease progression by targeting the fibrotic aspect of the ILD.\n\nLet's re-evaluate. The question asks for the best chance of *halting disease progression*. Anti-MDA5 positive ILD is characterized by rapid progression and often a poor prognosis. While rituximab targets the immune system, nintedanib directly targets the fibrotic process that leads to irreversible lung damage. In severe, progressive ILD, especially when conventional immunosuppression is not fully effective, antifibrotic therapy is a key strategy to slow or halt progression. Given the severity of the PFTs and the progressive nature, nintedanib is a strong contender.\n\nHowever, some studies suggest that rituximab can be effective in improving lung function in anti-MDA5 positive ILD. The choice between rituximab and nintedanib can be complex and depend on the specific clinical scenario and the balance between inflammation and fibrosis.\n\nLet's consider the options again in light of the rapid progression.\nA. Increase prednisone and add mycophenolate mofetil - likely insufficient for rapidly progressive ILD.\nB. Triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide - cyclophosphamide is not typically first-line for this specific ILD.\nC. Rituximab with continued azathioprine - a good option for the autoimmune component.\nD. Nintedanib with continued current immunosuppression - targets the fibrotic process, which is crucial for halting progression in severe ILD.\nE. Plasma exchange followed by IVIG maintenance - more for acute flares, not necessarily for halting chronic progressive ILD.\n\nGiven the rapid progression and severe PFTs, the focus is on halting irreversible damage. Nintedanib is specifically designed to slow the progression of fibrosing ILDs. While rituximab addresses the autoimmune cause, nintedanib addresses the consequence of that inflammation, which is fibrosis and lung function decline. In the context of severe, progressive ILD, an antifibrotic agent is often considered essential to halt progression.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-005", "question": "A 38-year-old man from Cambodia presents with 3 weeks of fever, headache, and altered mental status. CSF analysis shows opening pressure 32 cm H2O, WBC 180/μL (90% lymphocytes), protein 120 mg/dL, glucose 28 mg/dL (serum 110 mg/dL). India ink preparation shows encapsulated yeast. Cryptococcal antigen titer is 1:2048 in CSF. HIV testing is positive with CD4 count of 35 cells/μL. He is started on liposomal amphotericin B and flucytosine with daily therapeutic lumbar punctures. On day 10, repeat lumbar puncture shows opening pressure 38 cm H2O, CSF WBC 420/μL (85% lymphocytes), protein 180 mg/dL, and cryptococcal antigen titer 1:1024. He has worsening headache and new sixth nerve palsy. What is the most appropriate next step?", "options": ["Add dexamethasone for paradoxical immune reconstitution inflammatory syndrome", "Switch to high-dose fluconazole for amphotericin resistance", "Place a ventriculoperitoneal shunt for refractory elevated intracranial pressure", "Continue current antifungal therapy with more aggressive CSF drainage", "Initiate antiretroviral therapy immediately to improve immune function"], "answer": "D", "answer_index": 3, "explanation": "The rising CSF pleocytosis with persistent elevated opening pressure despite treatment represents ongoing cryptococcal meningitis with inadequate pressure management rather than treatment failure or IRIS (patient not yet on ART). The antigen titer is decreasing appropriately. Management requires more aggressive CSF drainage-either more frequent LPs or temporary lumbar drain placement. Corticosteroids are contraindicated in cryptococcal meningitis (increased mortality in COAT trial). VPS is reserved for truly refractory cases after optimizing medical management. Early ART initiation increases IRIS risk and mortality when started before 4-6 weeks of antifungal therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with cryptococcal meningitis in the setting of advanced HIV infection (CD4 count of 35 cells/μL). Despite initial treatment with liposomal amphotericin B and flucytosine, his symptoms are worsening, and his intracranial pressure (ICP) remains significantly elevated (opening pressure 38 cm H2O). The new sixth nerve palsy is a sign of increased ICP.\n\nLet's analyze the options:\n\nA. Add dexamethasone for paradoxical immune reconstitution inflammatory syndrome (IRIS): While IRIS is a possibility in patients starting ART, the current presentation is more indicative of uncontrolled cryptococcal infection and elevated ICP. Dexamethasone might be considered for IRIS if it develops *after* starting ART, but it's not the primary management for uncontrolled cryptococcal meningitis with high ICP.\n\nB. Switch to high-dose fluconazole for amphotericin resistance: Amphotericin B is the initial drug of choice for severe cryptococcal meningitis. Resistance to amphotericin B is rare. The current regimen includes both amphotericin B and flucytosine, which is appropriate. Switching to fluconazole without evidence of resistance is not indicated.\n\nC. Place a ventriculoperitoneal shunt for refractory elevated intracranial pressure: The patient has persistently elevated ICP (32 cm H2O initially, now 38 cm H2O) and worsening neurological symptoms (headache, sixth nerve palsy). Therapeutic lumbar punctures are being performed, but the ICP remains high. A ventriculoperitoneal (VP) shunt is a definitive treatment for refractory elevated ICP in cryptococcal meningitis, especially when medical management fails to control it.\n\nD. Continue current antifungal therapy with more aggressive CSF drainage: While continuing antifungal therapy is crucial, \"more aggressive CSF drainage\" is vague. Therapeutic lumbar punctures are already being performed. If these are insufficient to control ICP, a more definitive intervention like a shunt is needed. Simply continuing the current approach without addressing the refractory ICP may lead to further neurological deterioration.\n\nE. Initiate antiretroviral therapy immediately to improve immune function: Starting ART is essential for long-term management of HIV and cryptococcal meningitis. However, guidelines recommend delaying ART initiation for 2-4 weeks after starting induction antifungal therapy for cryptococcal meningitis to avoid IRIS. In this case, the immediate concern is the uncontrolled infection and dangerously high ICP.\n\nConsidering the persistently elevated ICP and worsening neurological signs despite initial antifungal therapy and therapeutic lumbar punctures, the most appropriate next step is to address the refractory intracranial hypertension. A VP shunt is indicated for refractory elevated ICP in cryptococcal meningitis.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-006", "question": "A 67-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab develops progressive cognitive decline over 4 months. MRI brain shows multifocal white matter lesions without enhancement or mass effect. CSF shows 8 WBCs (all lymphocytes), protein 62 mg/dL, and negative routine cultures. JC virus PCR in CSF is positive with 850 copies/mL. Adalimumab is discontinued. Three weeks later, she develops new right hemiparesis and worsening confusion. Repeat MRI shows enlargement of lesions with new peripheral enhancement and edema. CSF now shows 45 WBCs (predominantly lymphocytes). What is the most appropriate management?", "options": ["Restart adalimumab to suppress destructive inflammation", "Initiate high-dose corticosteroids", "Begin cidofovir and cytarabine combination therapy", "Administer pembrolizumab to enhance JC virus clearance", "Perform brain biopsy to exclude CNS lymphoma"], "answer": "B", "answer_index": 1, "explanation": "This patient has developed immune reconstitution inflammatory syndrome (IRIS) following discontinuation of immunosuppression in the setting of PML. The new enhancement, edema, and increased CSF pleocytosis after stopping adalimumab are classic for PML-IRIS. High-dose corticosteroids are indicated to reduce the inflammatory response that, while representing immune recovery, can cause significant neurological damage. Restarting immunosuppression would be counterproductive. Cidofovir/cytarabine lack efficacy in PML. Pembrolizumab is used in refractory PML without immune reconstitution, not IRIS. Biopsy is unnecessary given confirmed JC virus and classic IRIS presentation.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with progressive cognitive decline, multifocal white matter lesions on MRI, and a positive JC virus PCR in the CSF, strongly suggestive of progressive multifocal leukoencephalopathy (PML). PML is a demyelinating disease caused by the JC virus, often occurring in immunocompromised individuals, including those on immunosuppressive therapies like methotrexate and adalimumab.\n\nThe initial management of PML is to discontinue the offending immunosuppressive agent, which was done with adalimumab. However, the patient's condition worsened with new neurological deficits and enhancing lesions on repeat MRI, indicating an immune reconstitution inflammatory syndrome (IRIS) or continued viral replication and damage.\n\nLet's analyze the options:\n\nA. Restarting adalimumab would further suppress the immune system, which is counterproductive in managing a viral infection like PML and would likely worsen the condition.\n\nB. Initiate high-dose corticosteroids are often used to manage PML-IRIS. The inflammatory response triggered by the immune system's attempt to clear the JC virus can cause significant neurological damage, and corticosteroids can help reduce this inflammation and edema, thereby improving neurological symptoms and preventing further damage. The worsening symptoms and new enhancement on MRI are highly suggestive of IRIS.\n\nC. Begin cidofovir and cytarabine combination therapy. While antiviral therapies have been explored for PML, their efficacy is limited, and they are not typically the first-line treatment, especially in the context of suspected IRIS. Cidofovir has significant nephrotoxicity, and cytarabine is an antimetabolite with its own toxicities.\n\nD. Administer pembrolizumab to enhance JC virus clearance. Pembrolizumab is an immune checkpoint inhibitor used in cancer treatment. It would enhance the immune response, which could be beneficial in clearing the virus, but it could also exacerbate IRIS and lead to more severe inflammation. It is not a standard treatment for PML.\n\nE. Perform brain biopsy to exclude CNS lymphoma. While CNS lymphoma is a differential diagnosis in immunocompromised patients with neurological symptoms and white matter lesions, the positive JC virus PCR in the CSF makes PML the most likely diagnosis. The progression of lesions with enhancement after stopping immunosuppression is also characteristic of PML-IRIS. A biopsy would be invasive and might not be necessary given the strong evidence for PML.\n\nConsidering the patient's worsening neurological status and the development of enhancing lesions after discontinuing adalimumab, the most appropriate management is to address the inflammatory response associated with the immune system's attempt to fight the JC virus. High-dose corticosteroids are the mainstay of treatment for PML-IRIS.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-007", "question": "A 29-year-old woman presents with 2 years of recurrent oral ulcers, genital ulcers, and bilateral anterior uveitis. She now develops sudden painless vision loss in her right eye. Examination reveals visual acuity of hand motion OD and 20/25 OS. Fundoscopy of the right eye shows diffuse retinal whitening with cherry-red spot and box-carring in retinal arterioles. Fluorescein angiography confirms central retinal artery occlusion. HLA-B51 is positive. Pathergy test is negative. What is the most appropriate immediate intervention to prevent contralateral involvement?", "options": ["High-dose intravenous methylprednisolone alone", "Infliximab infusion", "Combination of high-dose corticosteroids with cyclosporine", "Combination of high-dose corticosteroids with infliximab or adalimumab", "Anterior chamber paracentesis with ocular massage"], "answer": "D", "answer_index": 3, "explanation": "This patient has Behçet disease with ocular involvement including the devastating complication of retinal artery occlusion from retinal vasculitis. Immediate aggressive immunosuppression is critical to prevent bilateral blindness. Current evidence supports combination therapy with high-dose corticosteroids plus a TNF-alpha inhibitor (infliximab or adalimumab) as the most effective approach for severe ocular Behçet. Corticosteroids alone or with cyclosporine are insufficient for this severity. Anterior chamber paracentesis addresses embolic CRAO, not inflammatory vasculitic occlusion. The goal is preventing contralateral involvement through rapid inflammation control.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with a constellation of symptoms highly suggestive of Behçet's disease: recurrent oral ulcers, genital ulcers, and uveitis. The sudden painless vision loss in the right eye with fundoscopic findings of retinal whitening, cherry-red spot, and box-carring, confirmed by fluorescein angiography as central retinal artery occlusion (CRAO), is a severe ocular manifestation. The positive HLA-B51 further supports the diagnosis of Behçet's disease.\n\nThe question asks for the most appropriate immediate intervention to prevent contralateral involvement. CRAO is a serious complication that can lead to permanent vision loss. In Behçet's disease, vascular involvement, including arterial occlusions, is a significant concern.\n\nLet's analyze the options:\n\nA. High-dose intravenous methylprednisolone alone: Corticosteroids are a cornerstone of treatment for active inflammation in Behçet's disease, especially severe ocular manifestations. High-dose IV methylprednisolone is appropriate for acute, severe inflammation. However, for preventing further vascular events and contralateral involvement in a patient with established vascular occlusion, it might not be sufficient on its own, especially given the potential for recalcitrant disease.\n\nB. Infliximab infusion: Infliximab is a TNF-alpha inhibitor that is effective in managing various manifestations of Behçet's disease, including ocular and vascular involvement. It can be used as a steroid-sparing agent and for refractory cases. While effective, it might not be the *immediate* first-line intervention for acute CRAO and prevention of contralateral involvement when combined with other agents.\n\nC. Combination of high-dose corticosteroids with cyclosporine: Cyclosporine is an immunosuppressant that can be used in Behçet's disease, particularly for ocular involvement. Combining it with corticosteroids can provide potent immunosuppression. However, cyclosporine's efficacy in preventing arterial occlusions might be less established compared to TNF inhibitors in this context.\n\nD. Combination of high-dose corticosteroids with infliximab or adalimumab: This option combines the immediate anti-inflammatory effect of high-dose corticosteroids with the potent immunosuppressive and anti-vascular effect of a TNF inhibitor (infliximab or adalimumab). TNF inhibitors have shown significant efficacy in preventing and treating vascular complications in Behçet's disease, including arterial occlusions. This combination offers a robust approach to controlling the acute event and preventing further vascular events in the contralateral eye.\n\nE. Anterior chamber paracentesis with ocular massage: This is a procedure typically used for managing acute angle-closure glaucoma or to reduce intraocular pressure. It is not indicated for central retinal artery occlusion and would not address the underlying inflammatory and thrombotic processes causing the CRAO or prevent contralateral involvement.\n\nConsidering the severity of CRAO and the risk of contralateral involvement in Behçet's disease, a combination therapy that aggressively suppresses inflammation and targets the underlying vasculitis is crucial. High-dose corticosteroids provide immediate anti-inflammatory effects, while TNF inhibitors are highly effective in managing vascular complications and preventing recurrence. Therefore, the combination of high-dose corticosteroids with a TNF inhibitor is the most appropriate immediate intervention to prevent contralateral involvement.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-008", "question": "A 41-year-old man with no significant medical history presents with 6 weeks of progressive bilateral lower extremity weakness and paresthesias. He reports a diarrheal illness 8 weeks ago. Examination shows 3/5 strength in hip flexors, 4/5 in knee extensors, 4-/5 in ankle dorsiflexors bilaterally, absent deep tendon reflexes, and decreased vibration sense to the knees. Nerve conduction studies show reduced CMAP amplitudes with normal conduction velocities and no conduction block. Needle EMG shows active denervation in distal leg muscles. CSF protein is 95 mg/dL with 1 WBC. Anti-GM1 IgG antibodies are strongly positive. Despite 5 days of IVIG, he continues to worsen with new respiratory compromise requiring intubation. What is the next best step in management?", "options": ["Repeat IVIG course immediately", "Initiate plasma exchange", "Add high-dose intravenous methylprednisolone", "Begin eculizumab therapy", "Administer second IVIG course after 4-week interval"], "answer": "B", "answer_index": 1, "explanation": "This patient has acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome, evidenced by pure motor axonal pattern on NCS, anti-GM1 antibodies, and preceding Campylobacter-like illness. When patients fail to respond to initial IVIG and continue deteriorating, plasma exchange is the appropriate next step as it works through a different mechanism (antibody removal vs. immunomodulation). The treatments are not synergistic when given together but can be used sequentially. Corticosteroids are ineffective in GBS. Eculizumab has shown promise in refractory cases but is not yet standard of care. Waiting 4 weeks for repeat IVIG is inappropriate in a deteriorating patient.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with symptoms highly suggestive of Guillain-Barré syndrome (GBS), specifically a variant with features of both demyelination and axonal damage, given the reduced CMAP amplitudes and denervation on EMG. The history of diarrheal illness, the neurological findings (weakness, paresthesias, areflexia, sensory loss), and the elevated CSF protein with normal cell count are classic for GBS. The strongly positive anti-GM1 IgG antibodies suggest a possible variant like multifocal motor neuropathy (MMN) or a specific subtype of GBS, but the presentation is more acute and progressive than typical MMN.\n\nThe patient has not responded to 5 days of IVIG and is worsening, requiring intubation. This indicates a severe and potentially life-threatening course. In cases of GBS that are not responding to initial treatment or are rapidly progressing, plasma exchange is considered a standard second-line therapy. It aims to remove the antibodies and other inflammatory mediators responsible for nerve damage.\n\nLet's analyze the options:\n\nA. Repeat IVIG course immediately: While IVIG is a first-line treatment, repeating it immediately without a change in strategy might not be effective if the initial course was insufficient or if the underlying pathology requires a different approach.\n\nB. Initiate plasma exchange: Plasma exchange is a well-established treatment for GBS, particularly in cases that are severe, rapidly progressing, or not responding to IVIG. Given the patient's worsening condition and respiratory compromise despite IVIG, plasma exchange is a strong consideration.\n\nC. Add high-dose intravenous methylprednisolone: Corticosteroids are generally not recommended for typical GBS as they have not shown benefit and may even be detrimental.\n\nD. Begin eculizumab therapy: Eculizumab is a complement inhibitor and is used for conditions like atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). It is not a standard treatment for GBS.\n\nE. Administer second IVIG course after 4-week interval: While a second course of IVIG might be considered in some GBS cases, waiting 4 weeks is not indicated for a rapidly deteriorating patient. Furthermore, if the first course was ineffective, a different modality might be more appropriate.\n\nConsidering the lack of response to IVIG and the progressive deterioration, plasma exchange is the most appropriate next step in management.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-009", "question": "A 55-year-old woman with mechanical mitral valve replacement on warfarin presents with acute onset aphasia and right hemiplegia. Symptoms began 90 minutes ago. CT head shows no hemorrhage. CT angiography reveals left M1 occlusion. INR is 2.8. CT perfusion shows large penumbra with small core infarct (ASPECTS 8). Blood pressure is 165/95 mmHg. What is the most appropriate next step?", "options": ["Administer IV alteplase followed by endovascular thrombectomy", "Proceed directly to endovascular thrombectomy without IV thrombolysis", "Reverse anticoagulation with 4-factor PCC then administer IV alteplase", "Administer idarucizumab followed by IV alteplase", "Medical management only with blood pressure optimization"], "answer": "B", "answer_index": 1, "explanation": "In patients with acute ischemic stroke on therapeutic anticoagulation (INR >1.7), IV thrombolysis is contraindicated due to bleeding risk. However, mechanical thrombectomy is not contraindicated and should be pursued emergently in patients with large vessel occlusion and favorable perfusion imaging (large penumbra, small core). Reversing anticoagulation to give tPA adds delay and the combination increases bleeding risk. Idarucizumab reverses dabigatran, not warfarin. Medical management alone would result in completed large territory infarction given the M1 occlusion. Direct thrombectomy offers the best risk-benefit profile.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with acute ischemic stroke symptoms and a confirmed large vessel occlusion (LVO) on CT angiography. She is on warfarin, and her INR is 2.8, which is within the therapeutic range for mechanical mitral valve replacement.\n\nLet's analyze the options:\n\nA. Administer IV alteplase followed by endovascular thrombectomy: While alteplase is a standard treatment for acute ischemic stroke, its use in patients on warfarin with an INR of 2.8 is controversial due to increased bleeding risk. However, the guidelines for mechanical thrombectomy often allow for IV thrombolysis if the patient is a candidate and the INR is below a certain threshold (often <1.7 or <1.8, but some centers may consider up to 2.0 or even higher with careful risk assessment). Given the large penumbra and small core infarct (ASPECTS 8), reperfusion is highly desirable. The decision to give alteplase would depend on specific institutional protocols and a risk-benefit assessment.\n\nB. Proceed directly to endovascular thrombectomy without IV thrombolysis: Endovascular thrombectomy is indicated for LVO. In patients with contraindications to IV thrombolysis or when IV thrombolysis is not beneficial (e.g., due to time window or INR), direct thrombectomy is the preferred approach. Given the INR of 2.8, this is a strong consideration.\n\nC. Reverse anticoagulation with 4-factor PCC then administer IV alteplase: Reversing anticoagulation with 4-factor PCC is typically done when there is a contraindication to thrombolysis or when a significant bleed is present. While the INR is elevated, it's not extremely high, and the absence of hemorrhage on CT makes immediate reversal for the sole purpose of giving alteplase less straightforward, especially if direct thrombectomy is an option. However, if alteplase is to be given, reversing the INR would be a consideration.\n\nD. Administer idarucizumab followed by IV alteplase: Idarucizumab is a specific reversal agent for dabigatran (a direct thrombin inhibitor), not warfarin. Therefore, this option is incorrect.\n\nE. Medical management only with blood pressure optimization: Given the LVO and large penumbra, medical management alone is unlikely to be sufficient to restore perfusion and prevent further infarct expansion. Endovascular therapy is strongly indicated.\n\nConsidering the options and the patient's presentation:\nThe patient has a large vessel occlusion and a significant penumbra, making reperfusion therapy crucial.\nHer INR of 2.8 is a relative contraindication to IV alteplase, but not an absolute one, especially if the benefits of reperfusion outweigh the risks. However, it does raise concern.\nEndovascular thrombectomy is clearly indicated due to the LVO.\n\nThe question asks for the *most appropriate next step*. In the context of a large vessel occlusion and a significant penumbra, the primary goal is to restore blood flow. While IV alteplase can be beneficial, the INR of 2.8 makes it a less straightforward decision. Proceeding directly to endovascular thrombectomy is a safe and effective strategy for LVO, especially when there are concerns about IV thrombolysis. Many guidelines support direct thrombectomy in such scenarios. If alteplase were to be given, reversal of anticoagulation would be a prerequisite, making option C a possibility, but direct thrombectomy is often preferred when there's a contraindication or concern for IV thrombolysis.\n\nHowever, let's re-evaluate the typical management pathways. For LVO, the decision is often between IV alteplase + thrombectomy, or direct thrombectomy. The INR of 2.8 is a significant factor against immediate IV alteplase without reversal. If the goal is to achieve reperfusion quickly, and there's a concern with alteplase, direct thrombectomy becomes the most direct and appropriate next step to address the LVO.\n\nLet's consider the possibility of giving alteplase. If the INR was <1.7, option A would be more straightforward. With INR 2.8, the risk of bleeding with alteplase is increased. Reversing with PCC (option C) would be a step to enable alteplase, but direct thrombectomy (option B) bypasses the need for IV thrombolysis and directly addresses the occlusion. Given the promptness of the symptoms and the large penumbra, rapid reperfusion is key.\n\nIn many stroke protocols, if a patient is a candidate for thrombectomy but has contraindications to IV thrombolysis (like a higher INR), they proceed directly to thrombectomy. The INR of 2.8 is a significant factor that would lead many clinicians to favor direct thrombectomy over IV alteplase, even with reversal.\n\nFinal consideration: The question asks for the *most appropriate next step*. Given the LVO and the INR of 2.8, proceeding directly to endovascular thrombectomy is a well-established and safe approach that directly addresses the occlusion and aims for rapid reperfusion.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-010", "question": "A 33-year-old woman with no prior cardiac history presents with progressive exertional dyspnea over 3 months. She delivered her third child 5 months ago. Echocardiogram shows left ventricular ejection fraction of 25%, LV end-diastolic diameter of 62 mm, moderate functional mitral regurgitation, and no thrombus. BNP is 1,850 pg/mL. She is started on guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Genetic testing reveals a truncating variant in the TTN gene. At 6-month follow-up, LVEF has improved to 40% but remains below normal. Which factor most strongly predicts her likelihood of complete LV recovery?", "options": ["Absence of late gadolinium enhancement on cardiac MRI", "Normalization of BNP levels", "Presence of the TTN truncating variant", "Baseline LVEF above 30%", "Multiparity status"], "answer": "A", "answer_index": 0, "explanation": "In peripartum cardiomyopathy, the absence of late gadolinium enhancement (LGE) on cardiac MRI is the strongest predictor of complete LV recovery, indicating absence of irreversible myocardial fibrosis. TTN truncating variants are actually associated with incomplete recovery and persistent LV dysfunction in PPCM, making option C incorrect. While BNP normalization and higher baseline LVEF are favorable, they are less predictive than LGE status. Multiparity is a risk factor for developing PPCM but does not predict recovery. LGE represents scar that cannot recover regardless of optimal medical therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The question asks about the factor that most strongly predicts the likelihood of *complete* LV recovery. Let's analyze the options:\n\nA. Absence of late gadolinium enhancement (LGE) on cardiac MRI is a strong predictor of myocardial recovery in various cardiomyopathies, particularly ischemic. In non-ischemic cardiomyopathies like peripartum cardiomyopathy (PPCM), the absence of LGE suggests less irreversible myocardial damage and a higher chance of recovery.\n\nB. Normalization of BNP levels is a marker of improvement in heart failure symptoms and cardiac strain, but it doesn't directly predict *complete* recovery of LV function. While improvement in BNP is good, it doesn't guarantee full LVEF normalization.\n\nC. The presence of a truncating variant in the TTN gene is associated with dilated cardiomyopathy and can predispose individuals to developing cardiomyopathy, including PPCM. However, the presence of the variant itself doesn't predict the *degree* of recovery. In fact, some genetic cardiomyopathies are associated with less favorable long-term outcomes.\n\nD. Baseline LVEF above 30% is a general indicator of less severe baseline dysfunction. The patient's baseline LVEF was 25%, which is severely reduced. While a higher baseline LVEF might correlate with better recovery potential, the question is about *complete* recovery, and the patient has already shown improvement from 25% to 40%. This option is less specific than others.\n\nE. Multiparity status (having had multiple children) is a risk factor for PPCM, but it does not predict the likelihood of recovery. The patient's history of three children and recent delivery is relevant to the diagnosis of PPCM, but not to the prognosis of recovery.\n\nConsidering the options, the absence of LGE on cardiac MRI is the strongest predictor of significant myocardial recovery in cardiomyopathies, suggesting a lack of irreversible fibrosis. While the patient has shown improvement, complete recovery is the key. LGE indicates scar tissue, which is generally not reversible. Therefore, its absence suggests a greater potential for the remaining viable myocardium to recover function.\n\nThe final answer is $\\boxed{A}$."}]